Okano, Naohiro
Naruge, Daisuke
Kawai, Kirio
Kobayashi, Takaaki
Nagashima, Fumio
Endou, Hitoshi
Furuse, Junji
Funding for this research was provided by:
J-Pharma Co., Ltd.
Article History
Received: 6 February 2020
Accepted: 11 March 2020
First Online: 20 March 2020
Compliance with ethical standards
:
: Okano N. received personal fees from Merck Serono, Taiho, Eisai and J-Pharma. Naruge D. declares that he has no conflict of interest. Kawai K. declares that he has no conflict of interest. Kobayashi T. declares that he has no conflict of interest. Nagashima F. received personal fees from Taiho, Chugai, Yakult, Sumitomo Dainippon, Merck Serono, Takeda, Kyowa Hakko Kirin, Sanofi Mochida, Janssen and Nestle. Endou H. received salary from J-Pharma, and has pending patents for LAT1, JPH203 and application of JPH203 in Phase I study of solid tumors. Furuse J. received grants from J-Pharma, Taiho, Sumitomo Dainippon, Janssen, Daiichi Sankyo, MSD, Yakult, Takeda, Chugai, Ono, Astellas, Zeria, Novartis, Nanocarrier, Shionogi, Onco Therapy Science, Eli Lilly Japan, Bayer, Bristol-Myers Squibb, Merck Serono, Kyowa Hakko Kirin, Eisai, NanoCarrier, Mochida, Baxalta and Sanofi, and received personal fees from Taiho, Chugai, Yakult, Sumitomo Dainippon, Eli Lilly Japan, Astellas, Ono, Pfizer, Bayer, Novartis, Merck Serono, Takeda, Eisai, MSD, Shionogi, J-Pharma, Daiichi Sankyo, Kyowa Hakko Kirin, Sanofi, Sandoz, Otsuka, Zeria, Fujifilm, Astra Zeneca, Asahi Kasei, Shire, Mochida, Nippon Kayaku, EA pharma, Sawai and Teijin Pharma.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the Institutional Review Board and with the 1964 Helsinki declaration and its later amendments. This article does not contain any studies with animals performed by any of the authors.
: Informed consent was obtained from all individual participants included in the study.